Bangladesh
· Delayed Price · Currency is BDT Advent Pharma Statistics
Total Valuation
Advent Pharma has a market cap or net worth of BDT 1.60 billion. The enterprise value is 1.67 billion.
| Market Cap | 1.60B |
| Enterprise Value | 1.67B |
Important Dates
The last earnings date was Monday, October 28, 2024.
| Earnings Date | Oct 28, 2024 |
| Ex-Dividend Date | Nov 21, 2024 |
Share Statistics
Advent Pharma has 93.13 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 93.13M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 8.31% |
| Owned by Institutions (%) | n/a |
| Float | 65.17M |
Valuation Ratios
The trailing PE ratio is 19.11.
| PE Ratio | 19.11 |
| Forward PE | n/a |
| PS Ratio | 2.81 |
| PB Ratio | 1.10 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 122.50 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.87, with an EV/FCF ratio of 128.00.
| EV / Earnings | 19.93 |
| EV / Sales | 2.93 |
| EV / EBITDA | 7.87 |
| EV / EBIT | 11.46 |
| EV / FCF | 128.00 |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.28 |
| Quick Ratio | 0.78 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.36 |
| Debt / FCF | 5.81 |
| Interest Coverage | 11.36 |
Financial Efficiency
Return on equity (ROE) is 5.86% and return on invested capital (ROIC) is 6.05%.
| Return on Equity (ROE) | 5.86% |
| Return on Assets (ROA) | 5.01% |
| Return on Capital (ROIC) | 6.05% |
| Revenue Per Employee | 1.80M |
| Profits Per Employee | 264,962 |
| Employee Count | 317 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 4.67 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.56% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -24.56% |
| 50-Day Moving Average | 19.42 |
| 200-Day Moving Average | 25.07 |
| Relative Strength Index (RSI) | 46.16 |
| Average Volume (20 Days) | 1,131,469 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Advent Pharma had revenue of BDT 571.67 million and earned 83.99 million in profits. Earnings per share was 0.90.
| Revenue | 571.67M |
| Gross Profit | 228.19M |
| Operating Income | 146.10M |
| Pretax Income | 103.78M |
| Net Income | 83.99M |
| EBITDA | 212.03M |
| EBIT | 146.10M |
| Earnings Per Share (EPS) | 0.90 |
Balance Sheet
The company has 3.97 million in cash and 76.01 million in debt, giving a net cash position of -72.04 million or -0.77 per share.
| Cash & Cash Equivalents | 3.97M |
| Total Debt | 76.01M |
| Net Cash | -72.04M |
| Net Cash Per Share | -0.77 |
| Equity (Book Value) | 1.47B |
| Book Value Per Share | 15.65 |
| Working Capital | 53.20M |
Cash Flow
In the last 12 months, operating cash flow was 175.13 million and capital expenditures -162.06 million, giving a free cash flow of 13.08 million.
| Operating Cash Flow | 175.13M |
| Capital Expenditures | -162.06M |
| Free Cash Flow | 13.08M |
| FCF Per Share | 0.14 |
Margins
Gross margin is 39.92%, with operating and profit margins of 25.56% and 14.69%.
| Gross Margin | 39.92% |
| Operating Margin | 25.56% |
| Pretax Margin | 18.15% |
| Profit Margin | 14.69% |
| EBITDA Margin | 37.09% |
| EBIT Margin | 25.56% |
| FCF Margin | 2.29% |
Dividends & Yields
This stock pays an annual dividend of 0.20, which amounts to a dividend yield of 1.16%.
| Dividend Per Share | 0.20 |
| Dividend Yield | 1.16% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 9.76% |
| Buyback Yield | n/a |
| Shareholder Yield | 1.16% |
| Earnings Yield | 5.23% |
| FCF Yield | 0.82% |
Stock Splits
The last stock split was on February 28, 2022. It was a forward split with a ratio of 1.02.
| Last Split Date | Feb 28, 2022 |
| Split Type | Forward |
| Split Ratio | 1.02 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |